Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare ConferenceGlobeNewsWire · Oct 14, 2026
Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC)Defense World · Oct 1, 2026
New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)GlobeNewsWire · Sep 24, 2026
Tvardi Therapeutics to Participate in Upcoming Investor EventsGlobeNewsWire · Aug 26, 2026
Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis TranscriptSeeking Alpha · Aug 19, 2026
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business UpdateGlobeNewsWire · Aug 14, 2026Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.70 | -$0.69 | Beat |
| May 8, 2026 | -$0.65 | -$0.73 | Miss |
| Mar 31, 2026 | -$0.55 | -$0.78 | Miss |
| Nov 13, 2025 | -$0.83 | -$0.59 | Beat |
| Aug 14, 2025 | -$0.51 | -$1.00 | Miss |
| May 13, 2025 | -$0.59 | -$3.22 | Miss |